{"id":20270,"date":"2024-04-17T10:54:33","date_gmt":"2024-04-17T14:54:33","guid":{"rendered":"https:\/\/arsacs.com\/?p=20270"},"modified":"2026-03-16T18:16:11","modified_gmt":"2026-03-16T22:16:11","slug":"cpta-highlights-for-ataxias","status":"publish","type":"post","link":"https:\/\/2026.arsacs.com\/fr\/cpta-highlights-for-ataxias\/","title":{"rendered":"CPTA Highlights for Ataxias"},"content":{"rendered":"<p>Founded in 2021, Critical Path for Therapeutics for the Ataxias (CPTA) is a consortium focused on accelerating therapeutic development for Ataxias. The Ataxia Charlevoix- Saguenay Foundation is a member of the consortium. <a href=\"https:\/\/2026.arsacs.com\/wp-content\/uploads\/2024\/04\/CPTA-Highlights-ARSACS_mars2024.pdf\">Consortium Hig<\/a><a href=\"https:\/\/2026.arsacs.com\/wp-content\/uploads\/2024\/04\/CPTA-Highlights-ARSACS_mars2024.docx\">hlights and Achievements.<\/a><\/p>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Founded in 2021, Critical Path for Therapeutics for the Ataxias (CPTA) is a consortium focused on accelerating therapeutic development for Ataxias. The Ataxia Charlevoix- Saguenay Foundation is a member of the consortium. Consortium Highlights and Achievements.<\/p>","protected":false},"author":3,"featured_media":20284,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-20270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/20270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/comments?post=20270"}],"version-history":[{"count":7,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/20270\/revisions"}],"predecessor-version":[{"id":24971,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/20270\/revisions\/24971"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/media\/20284"}],"wp:attachment":[{"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/media?parent=20270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/categories?post=20270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/2026.arsacs.com\/fr\/wp-json\/wp\/v2\/tags?post=20270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}